Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
no dilution/ PMCB MMMW
maybe for 2016/ $SIPC recent news/filings recent news 12-23-15
## source: finance.yahoo.com
Wed, 23 Dec 2015 13:30:00 GMT ~ Sipp Industries Announces Official Opening of New Subsidiary Major Hemp
[Marketwired] - Sipp Industries, Inc. , a diversified conglomerate corporation specializing in technology, manufacturing and distribution of commercial and consumer products announces the opening of Major Hemp at www.majorhemp.com....
read full: http://finance.yahoo.com/news/sipp-industries-announces-official-opening-133000136.html
*********************************************************
Tue, 15 Dec 2015 18:04:25 GMT ~ SIPP INDUSTRIES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=sipc
*********************************************************
Tue, 14 Jul 2015 12:05:00 GMT ~ Sipp Industries Launches Online Store Offering Bulk Hemp Products and Co-Packaging Solutions for Expanding Hemp Industry
[PR Newswire] - COSTA MESA, Calif., July 14, 2015 /PRNewswire/ -- Sipp Industries, Inc. (OTC Markets: SIPC), a diversified conglomerate corporation specializing in technology and distribution of consumer products, announces ...
read full: http://finance.yahoo.com/news/sipp-industries-launches-online-store-120500277.html
*********************************************************
Tue, 23 Jun 2015 12:04:00 GMT ~ Sipp Industries Launches Vertically Integrated Solutions for Growing Hemp Industry
[PR Newswire] - COSTA MESA, Calif., June 23, 2015 /PRNewswire/ -- Sipp Industries, Inc. (OTC Markets: SIPC), a diversified conglomerate corporation specializing in technology and distribution of consumer products expands ...
read full: http://finance.yahoo.com/news/sipp-industries-launches-vertically-integrated-120400281.html
*********************************************************
Tue, 09 Jun 2015 13:04:00 GMT ~ Sipp Industries Forms New Business Unit for Bulk Hemp Distribution
[PR Newswire] - COSTA MESA, Calif., June 9, 2015 /PRNewswire/ – Sipp Industries, Inc. (OTC Markets: SIPC), a diversified conglomerate corporation specializing in technology and distribution of consumer products, announces ...
read full: http://finance.yahoo.com/news/sipp-industries-forms-business-unit-130400673.html
*********************************************************
$SIPC charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$SIPC company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/SIPC/company-info
Ticker: $SIPC
OTC Market Place: OTC Pink Current
CIK code: 0000943653
Company name: Sipp Industries, Inc.
Company website: http://www.sippindustries.com
Incorporated In: NV, USA
Business Description: Sipp Industries is a holding company that specializes in import export, licensing and distribution of commercial and consumer products.
$SIPC share structure
## source: otcmarkets.com
Market Value: $1,901,751 a/o Dec 22, 2015
Shares Outstanding: 543,357,488 a/o Sep 30, 2015
Float: 115,737,488 a/o Sep 30, 2015
Authorized Shares: 888,000,000 a/o Sep 30, 2015
Par Value: No Par Value
$SIPC extra dd links
Company name: Sipp Industries, Inc.
Company website: http://www.sippindustries.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SIPC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SIPC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SIPC+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SIPC/news - http://finance.yahoo.com/q/h?s=SIPC+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SIPC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SIPC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SIPC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SIPC
DTCC (dtcc.com): http://search2.dtcc.com/?q=Sipp+Industries%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Sipp+Industries%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Sipp+Industries%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.sippindustries.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.sippindustries.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.sippindustries.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SIPC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000943653&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SIPC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SIPC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SIPC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SIPC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SIPC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SIPC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SIPC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SIPC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SIPC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SIPC+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SIPC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SIPC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SIPC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SIPC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SIPC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SIPC/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (hppt://www.pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SIPC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SIPC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SIPC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SIPC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SIPC
$SIPC DD Notes ~ http://www.ddnotesmaker.com/SIPC
Great new year for $PMCB and $MMMW.
Toxic debt is horrible and the worst thing going for OTC stocks. I am glad that MMMW rejects toxic debt. Now , I am upset that I am reminded that many people do not take toxic debt seriously. I will write every congressman that I contributed financially to ban toxic debt. I guess that I could thankful for the general lack of understanding of many investors for reminding me that maybe Congress does not understand it like many people do not understand it. Marry Christmas to everyone even to the many misguided souls who do not understand toxic debt. God Bless everyone.
Death Spiral and Ghost Busters / http://www.barchart.com/quotes
http://investorshub.advfn.com/Death-Spiral-and-Ghost-Busters-29759/
http://investorshub.advfn.com/Death-Spiral-and-Ghost-Busters-29759/
http://www.barchart.com/quotes/stocks/UAPC
http://www.barchart.com/quotes/stocks/MBHC
http://www.barchart.com/quotes/stocks/ITKH
http://www.barchart.com/quotes/stocks/MMMW
http://www.barchart.com/quotes/stocks/MVTG
http://www.barchart.com/quotes/stocks/VMRI
UAPC MBHC ITKH MMMW MVTG VMRI
http://www.barchart.com/quotes/stocks/CRDC
http://www.barchart.com/quotes/stocks/VPRO
http://www.barchart.com/quotes/stocks/PNTV
http://www.barchart.com/quotes/stocks/BRWC
http://www.barchart.com/quotes/stocks/POTG
CRDC VPRO PNTV BRWC POTG
------------------------------------------------
http://www.barchart.com/quotes/stocks/OGZPY
http://www.barchart.com/quotes/stocks/INMG
http://www.barchart.com/quotes/stocks/GBGM
NOW INMG
http://www.barchart.com/quotes/stocks/KWBT
http://www.barchart.com/quotes/stocks/PMCB
http://www.barchart.com/quotes/stocks/JNSH
OGZPY GBGM INMG KWBT PMCB JNSH
http://www.barchart.com/quotes/stocks/MMRF
http://www.barchart.com/quotes/stocks/FIT
http://www.barchart.com/quotes/stocks/OWOO
http://www.barchart.com/quotes/stocks/ISBG
http://www.barchart.com/quotes/stocks/SSYS
http://www.barchart.com/quotes/stocks/CMGO
MMRF FIT OWOO ISBG SSYS CMGO
------------------------------------------------
http://www.barchart.com/quotes/stocks/ROYL
http://www.barchart.com/quotes/stocks/ONCI
http://www.barchart.com/quotes/stocks/DIRV
http://www.barchart.com/quotes/stocks/DSCR
http://www.barchart.com/quotes/stocks/WPWR
ROYL ONCI DIRV DSCR WPWR
http://www.barchart.com/quotes/stocks/TUNG
http://www.barchart.com/quotes/stocks/GNPT
http://www.barchart.com/quotes/stocks/ZMRK
http://www.barchart.com/quotes/stocks/DCAC
http://www.barchart.com/quotes/stocks/IDGC
http://www.barchart.com/quotes/stocks/PYHH
TUNG GNPT ZMRK DCAC IDGC INVESTOR 1 MILLION SHARES IN PYHH
-------------------------------------------------
http://www.barchart.com/quotes/stocks/NESV
http://www.barchart.com/quotes/stocks/IHSI
http://www.barchart.com/quotes/stocks/ISML
http://www.barchart.com/quotes/stocks/PXYN
http://www.barchart.com/quotes/stocks/IJJP
NESV IHSI ISML PXYN IJJP
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
http://www.barchart.com/quotes/stocks/
===========================================================
////////////////////////////////////////////////////////////
[-chart]stockcharts.com/c-sc/sc?s=DTTO&p=w&b=2&g=0&i=p69412508847[/chart]
////////////////////////////////////////////////////////////
WEEKLY, BLK, 50-MA, BB, SAR, PPS, VOL.,MFI, STOCHS/ INCREMENT QTR.
[-chart]stockcharts.com/c-sc/sc?s=LEXG&p=w&b=2&g=0&i=p69412508847[/chart]
WEEKLY, BLK, 50-MA, BB, SAR, PPS, VOL.,MFI, STOCHS/ INCREMENT QTR.
[-chart]stockcharts.com/c-sc/sc?s=GNPT&p=w&b=2&g=0&i=p69412508847[/chart]
DAILY, TONED BRN, RSI, A-D, 8-20-30 MA, VOL., MACD
[-chart]stockcharts.com/c-sc/sc?s=NGCG&p=D&yr=0&mn=9&dy=0&i=p83316375882&a=397578142&r=1425774813837[/chart]
DAILY, WHT., RSI, MACD, 50MA, 200MA, VOLIME,
[-chart]stockcharts.com/c-sc/sc?s=ZNGA&p=D&yr=0&mn=2&dy=0&i=t21771599565&r=1392585472122[/chart]
hi my friend, good afternoon.
Just checking in to see if all is well. Glad to hear it is.
Great new year both $PMCB and $MMMW
Sorry about being "out of town"
$PMCB PharmaCyte Biotech Designs Clinical Trial to Meet Critical Unmet Medical Need
Source: GlobeNewswire Inc.
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its upcoming clinical trial will determine whether its pancreatic cancer treatment (Cell-in-a-Box® capsules + low-doses of ifosfamide) can satisfy a critical unmet medical need for patients with pancreatic cancer when the “gold standard” treatment is no longer effective at treating the disease. Currently there is no adequate alternative treatment available.
Translational Drug Development (TD2), along with Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, and the Chairman of PharmaCyte Biotech’s Scientific Advisory Board, and Dr. Manuel Hidalgo, the Director of Clinical Research at the Spanish National Cancer Research Center and a member of PharmaCyte’s Scientific Advisory Board, provided invaluable information and guidance to PharmaCyte in the design of its clinical trial in advanced pancreatic cancer. The trial is designed to provide an effective treatment for the large percentage of patients who no longer respond to the “gold standard” for the treatment of advanced pancreatic cancer. There are few options for further treatment available to them, and these are only marginally effective. PharmaCyte’s team believes that it is here that PharmaCyte’s pancreatic cancer treatment could play an important role in what has been termed a “consolidation therapy” in the further treatment of these patients.
As previously explained by Dr. Löhr in his recent article on the unmet medical need being targeted by PharmaCyte, chemotherapy may be able to prevent relapse in patients whose pancreatic cancer tumors have been removed surgically, but this situation occurs in only 20% of all patients at best. The large remaining group of patients whose tumors are inoperable normally receive treatment designed to prolong survival. Recent progress in the chemotherapy of pancreatic cancer has resulted in survival rates of between 10 and 11 months through the use of either the combination of gemcitabine and nab-paclitaxel (Abraxane®), the “gold standard” for the treatment of pancreatic cancer, or a harsh combination of conventional cancer chemotherapy drugs known as FOLFIRINOX that not all patients can tolerate.
However, for patients whose tumors neither progress nor show signs of tumor reduction, there is no effective treatment alternative. PharmaCyte’s treatment of pancreatic cancer may fill this critical unmet medical need for these patients. This need and opportunity caused PharmaCyte to completely redesign its clinical trial.
In addition to examining the antitumor effectiveness of PharmaCyte’s pancreatic cancer treatment, the effect of the treatment on the development and progression of the pain associated with pancreatic cancer will also be measured in the clinical trial. Because this “pain” aspect will be studied, it will no longer be necessary to conduct a separate “pain” clinical trial as originally planned. The pain associated with pancreatic cancer is both unbearable and untreatable in about 25% of patients with the disease.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are extremely grateful to TD2, Dr. Löhr and Dr. Hidalgo for their insight and guidance in designing our clinical trial. We believe that their identification of the opportunity for our pancreatic cancer treatment to satisfy a critical unmet medical need will give our pancreatic cancer treatment the greatest opportunity for success. The inclusion of the previously planned separate pain trial in the upcoming trial will also eliminate the need for a costly and time-consuming separate trial to study this aspect of our pancreatic cancer treatment. Over the next week or so, we will be laying out our new trial design and the other changes related to the upcoming clinical trial.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte Biotech’s treatment for cancer involves encapsulating genetically modified live cells capable of converting an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
Primary Logo
Long term great future $PMCB and $MMMW. No toxic debt and little regular debt for $MMMW. Without toxic debt ,the value of $MMMW of the trading company is worth $600,000 while the market cap is now only $250,000. Any announcement of revenue could bring the value higher than solar companies with no revenue and toxic debt that have several million dollars in market cap valuation.There would be little upside barriers to stock price upside movement on good news without toxic debt weighing it down.
$PMCB PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
Source: GlobeNewswire Inc.
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree that highlights the key aspects of PharmaCyte’s new pancreatic cancer clinical trial design.
Listen to the interview here: http://www.stockmarketmediagroup.com/wp-content/uploads/2015/10/PharmaCyte_Biotech_CEO_Interview.mp3
The interview walks the audience through PharmaCyte’s last three press releases that announce the change in its clinical trial design. In the interview, PharmaCyte’s Chief Executive Officer and Chief Operating Officer discuss PharmaCyte’s efforts to address an unmet medical need with PharmaCyte’s pancreatic cancer treatment, why the trial was moved to the United States under the direction of Translational Drug Development (TD2) and some of the specifics related to the new trial design.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells capable of converting an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
Primary Logo
$PMCB PharmaCyte Biotech’s Encapsulation Technology Could Address Unmet Medical Need
Source: GlobeNewswire Inc.
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, released today the second in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. This latest article, written by Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, and the Chairman of PharmaCyte Biotech’s Scientific Advisory Board, discusses the unmet clinical need of a large group of patients suffering from locally advanced pancreatic cancer.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented on Dr. Löhr’s article, “Dr. Löhr understands the severity of the unmet medical need he addresses in his article as much as anyone. Dr. Löhr explains his rationale for believing there is an urgent need to develop a therapy for patients with pancreatic cancer that is not currently being addressed by the medical community. Our other prominent oncologists also believe that new therapeutic options are needed for those with locally advanced pancreatic cancer. We agree with Dr. Löhr that PharmaCyte Biotech’s pancreatic cancer treatment has the potential to address squarely this unmet medical need.”
The Unmet Clinical Need in Locally Advanced Pancreatic Cancer
Pancreatic cancer is a medical emergency(1). There is a highly unmet medical need for all patients as survival rates from pancreatic cancer are the lowest of all solid tumors. If nothing happens to change that situation, pancreatic cancer will become the number two cause of cancer-related deaths by 2030(2). There is evidence for the use of chemotherapy to prevent possible relapse in patients whose pancreatic cancer tumors have been removed surgically, but this situation occurs in only 20% of all patients at best.
The large remaining group of patients whose tumors are inoperable may receive palliative chemotherapy (treatment designed to prolong survival and ease symptoms), but these patients only exhibit survival rates oscillating around 6 months. Recent progress in the chemotherapy of pancreatic cancer has pushed this survival to 10-11 months through the use of either the combination of gemcitabine and nab-paclitaxel (Abraxane®)(3) or a rather harsh combination of conventional cancer chemotherapy drugs, known as FOLFIRINOX, that not all patients can tolerate(4).
These therapeutic strategies are part of recent guidelines for the treatment of pancreatic cancer. In addition, evidence for “second-line” therapy for patients whose tumors continue to grow exists(5). There is, however, a group of patients for whom we have nothing to offer today: patients with locally advanced disease (LAD) whose tumors are inoperable due to overgrowth of the arterial blood vessels, namely the superior mesenteric artery (SMA) or the celiac trunk. Current practice is to treat these patients with what is termed “neoadjuvant” chemotherapy using gemcitabine plus nab-paclitaxel (Abraxane®) or FOLFIRINOX to reduce the size of their tumors to the point where they become operable. This strategy works in only about 20% of patients with LAD.
In about 30% of patients, while they are receiving neoadjuvant chemotherapy, their tumors advance and metastasize (spread to other organs). This makes their primary pancreatic cancer tumors no longer eligible for curative surgery, and therapy is usually continued as a palliative measure. However, for the group (about 50%) of patients whose tumors neither progress nor show signs of tumor reduction, i.e. patients who exhibit stable disease, there is no effective treatment alternative. For this cadre of patients, a localized tumor therapy, such as that being developed by PharmaCyte Biotech, could present a welcomed therapeutic option.
PharmaCyte Biotech’s combination of encapsulated, live genetically-engineered cells capable of converting the cancer drug ifosfamide into its cancer-killing form implanted at the site of the tumor, followed by low doses of intravenously administered ifosfamide(6), may fill the unmet medical need that has escaped the medical community for far too many years. Results derived from the pending Phase 2b clinical trial could provide critical data to confirm this.
References:
1. Löhr JM. Personal view: Pancreatic cancer should be treated as a medical emergency. British Medical Journal, 2014; Vol. 349:g52612.
2. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 2014; Vol. 74:2913-2921.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine, 2013; Vol. 369:1691-1703.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine, 2011; Vol. 364:1817-1825.
5. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. European Journal of Cancer, 2011; Vol. 47:1676-1681.
6. Löhr M, Hoffmeyer A, Kroger J, et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet, 2001; Vol. 357:1591-1592.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte Biotech’s treatment for cancer involves encapsulating genetically modified live cells capable of converting an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
Primary Logo
$IDGC recent news/filings holds 1 million shares of PYHH
## source: finance.yahoo.com
Sat, 12 Sep 2015 17:04:05 GMT ~ IDGLOBAL CORP Financials
read full: http://finance.yahoo.com/q/is?s=idgc
*********************************************************
Mon, 03 Aug 2015 16:37:00 GMT ~ ID Global Corporation Forms a Strategic Alliance with Cannaworx, Inc.
[Accesswire] - CHICAGO, IL / ACCESSWIRE / August 3, 2015 / ID Global Corp. (OTC: IDGC) is pleased to announce that it has formed a strategic alliance with Cannaworx, Inc. whereby IDGC has acquired a 10% Profit Participation ...
read full: http://finance.yahoo.com/news/id-global-corporation-forms-strategic-163700600.html
*********************************************************
Wed, 15 Jul 2015 13:41:00 GMT ~ ID Global Corporation Financial Results for the First Quarter of 2015
[Accesswire] - CHICAGO, IL / ACCESSWIRE / July 15, 2015 / ID Global Corp. (OTC: IDGC) is pleased to announce that it has completed and released its first quarter financials for 2015. Revenue for the quarter included ...
read full: http://finance.yahoo.com/news/id-global-corporation-financial-results-134100504.html
*********************************************************
Tue, 14 Jul 2015 10:00:00 GMT ~ ID Global Corporation Selected for Inclusion in the MJIC US Non Reporting Index
[Accesswire] - CHICAGO, IL / ACCESSWIRE / July 14, 2015 / ID Global Corporation (PINKSHEETS: IDGC), a diversified holdings company with a focus on emerging and middle market investment opportunities in North America, ...
read full: http://finance.yahoo.com/news/id-global-corporation-selected-inclusion-100000440.html
*********************************************************
Mon, 13 Jul 2015 22:24:00 GMT ~ ID Global Corporation and Subsidiary Consolidated Financial Statements As of December 31, 2014
[Accesswire] - CHICAGO, IL / ACCESSWIRE / July 13, 2015 / I hereby certify that the accompanying unaudited financial statements and related footnotes and supplementary information hereto are based on the best information ...
read full: http://finance.yahoo.com/news/id-global-corporation-subsidiary-consolidated-222400749.html
*********************************************************
$IDGC charts
basic chart ## source: stockcharts.com
[-img]stockcharts.com/c-sc/sc?s=IDGC&p=D&b=5&g=0&id=p95448242713[/img]
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
[-img]stockcharts.com/c-sc/sc?chart=IDGC,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b[/img]
big weekly chart ## source: stockcharts.com
[-img]stockcharts.com/c-sc/sc?chart=IDGC,uu[e,a]whclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b[/img]
$IDGC company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/IDGC/company-info
Ticker: $IDGC
OTC Market Place: OTC Pink Current
CIK code: 0001391143
Company name: IDGlobal Corp.
Company website: http://www.idglobal-corp.com
Incorporated In: NV, USA
Business Description: Executive Management and Finance
$IDGC share structure
## source: otcmarkets.com
Market Value: $462,692 a/o Oct 23, 2015
Shares Outstanding: 4,626,915,257 a/o Jul 23, 2015
Float: 2,687,915,257 a/o Jul 23, 2015
Authorized Shares: 7,500,000,000 a/o Nov 18, 2014
Par Value: 0.00001
$IDGC extra dd links
Company name: IDGlobal Corp.
Company website: http://www.idglobal-corp.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=IDGC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=IDGC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=IDGC+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/IDGC/news - http://finance.yahoo.com/q/h?s=IDGC+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/IDGC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/IDGC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=IDGC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/IDGC
DTCC (dtcc.com): http://search2.dtcc.com/?q=IDGlobal+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=IDGlobal+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=IDGlobal+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.idglobal-corp.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.idglobal-corp.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.idglobal-corp.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/IDGC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001391143&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/IDGC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/IDGC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=IDGC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=IDGC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/IDGC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=IDGC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=IDGC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=IDGC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=IDGC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=IDGC+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/IDGC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=IDGC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/IDGC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=IDGC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/IDGC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/IDGC/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/IDGC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/IDGC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/IDGC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=IDGC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=IDGC
$IDGC DD Notes ~ http://www.ddnotesmaker.com/IDGC
good evening, mmmw pmcb look good.
VTMB MOVED TODAY FOR US.
3'S didn't get 5's though
RE;
Hey, thanks for telling me about VTMB. I took a small position in it 2 weeks ago and just like that, it ran. I appreciate it.
File Msg | Remove Msg | *Private* Reply
Ignore User
Block OTC_Skywalker's Private Messages
Follow User
Follow OTC_Skywalker
In Reply To: this message
mick Member Level
Wednesday, October 14, 2015 3:23:10 PM
on this one lot of chatter/
i don't trust mgmt /////\\\\\
group on twtr said like SIRG
that cae out after posted some negatives.
tried to reverse trend there
so far so good.
techs rally only.
M.O.U. not confirmed 49 days.
re;
Good day my friend. Can you give me the low down on SIRG? I bailed out yesterday myself because I needed to free up funds.
My friend is knees deep in this thing and sitting at a 50% loss.
This was supposed to run like crazy once the Q came off, but it really did nothing.
I see you once supported it, but then had a change of heart.
What did you learn that made you change your opinion? Should I consider taking up another position here?
i would look at vtmb some some.
i updated ibox.
it will go.
VTMB Vitamin Blue Inc. 12,576 5 hours ago Retail - Wholesale Distributors
http://investorshub.advfn.com/boards/getboards.aspx?searchstr=vtmb
http://investorshub.advfn.com/Vitamin-Blue-Inc-VTMB-25901/
Sat, 29 Aug 2015 17:04:11 GMT ~ VITAMIN BLUE, INC. Financials
read full: http://finance.yahoo.com/q/is?s=vtmb
*********************************************************
Fri, 17 Jul 2015 12:30:00 GMT ~ Vitamin Blue Begins Testing Ads on Facebook
[Marketwired] - Vitamin Blue is beginning to test ads on the popular social network Facebook. This comes on the heels of ramping up online marketing initiatives this year to increase online sales. So far those initiatives ...
read full: http://finance.yahoo.com/news/vitamin-blue-begins-testing-ads-123000550.html
*********************************************************
Tue, 07 Jul 2015 12:30:00 GMT ~ Vitamin Blue Sales up in Q2, Increase of 35% Year Over Year
[Marketwired] - Vitamin Blue announced results for Q2 and is doing strong with an increase in sales of 35% year over year. Ecommerce initiatives have been performing strong. Sales on VitaminBlue.com were up 49% year over ...
read full: http://finance.yahoo.com/news/vitamin-blue-sales-q2-increase-123000718.html
*********************************************************
Market Value: $484,022 a/o Oct 05, 2015
Shares Outstanding: 1,613,405,000 a/o Jun 30, 2015
Float: 473,330,000 a/o Jun 30, 2015
Authorized Shares: 4,900,000,000 a/o Jun 30, 2015
(Watch PMCB) New MMMW solar tracker revenue will help in both the short term and long term. Market cap and debt is very very low.
Great new products $PMCB and $MMMW
$PMCB PharmaCyte Biotech Designs Clinical Trial to Meet Critical Unmet Medical Need
Source: GlobeNewswire Inc.
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its upcoming clinical trial will determine whether its pancreatic cancer treatment (Cell-in-a-Box® capsules + low-doses of ifosfamide) can satisfy a critical unmet medical need for patients with pancreatic cancer when the “gold standard” treatment is no longer effective at treating the disease. Currently there is no adequate alternative treatment available.
Translational Drug Development (TD2), along with Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, and the Chairman of PharmaCyte Biotech’s Scientific Advisory Board, and Dr. Manuel Hidalgo, the Director of Clinical Research at the Spanish National Cancer Research Center and a member of PharmaCyte’s Scientific Advisory Board, provided invaluable information and guidance to PharmaCyte in the design of its clinical trial in advanced pancreatic cancer. The trial is designed to provide an effective treatment for the large percentage of patients who no longer respond to the “gold standard” for the treatment of advanced pancreatic cancer. There are few options for further treatment available to them, and these are only marginally effective. PharmaCyte’s team believes that it is here that PharmaCyte’s pancreatic cancer treatment could play an important role in what has been termed a “consolidation therapy” in the further treatment of these patients.
As previously explained by Dr. Löhr in his recent article on the unmet medical need being targeted by PharmaCyte, chemotherapy may be able to prevent relapse in patients whose pancreatic cancer tumors have been removed surgically, but this situation occurs in only 20% of all patients at best. The large remaining group of patients whose tumors are inoperable normally receive treatment designed to prolong survival. Recent progress in the chemotherapy of pancreatic cancer has resulted in survival rates of between 10 and 11 months through the use of either the combination of gemcitabine and nab-paclitaxel (Abraxane®), the “gold standard” for the treatment of pancreatic cancer, or a harsh combination of conventional cancer chemotherapy drugs known as FOLFIRINOX that not all patients can tolerate.
However, for patients whose tumors neither progress nor show signs of tumor reduction, there is no effective treatment alternative. PharmaCyte’s treatment of pancreatic cancer may fill this critical unmet medical need for these patients. This need and opportunity caused PharmaCyte to completely redesign its clinical trial.
In addition to examining the antitumor effectiveness of PharmaCyte’s pancreatic cancer treatment, the effect of the treatment on the development and progression of the pain associated with pancreatic cancer will also be measured in the clinical trial. Because this “pain” aspect will be studied, it will no longer be necessary to conduct a separate “pain” clinical trial as originally planned. The pain associated with pancreatic cancer is both unbearable and untreatable in about 25% of patients with the disease.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are extremely grateful to TD2, Dr. Löhr and Dr. Hidalgo for their insight and guidance in designing our clinical trial. We believe that their identification of the opportunity for our pancreatic cancer treatment to satisfy a critical unmet medical need will give our pancreatic cancer treatment the greatest opportunity for success. The inclusion of the previously planned separate pain trial in the upcoming trial will also eliminate the need for a costly and time-consuming separate trial to study this aspect of our pancreatic cancer treatment. Over the next week or so, we will be laying out our new trial design and the other changes related to the upcoming clinical trial.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte Biotech’s treatment for cancer involves encapsulating genetically modified live cells capable of converting an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
Primary Logo
NECA about to test .00s breakout
NECA Office location in todays filings: https://www.google.com/maps/place/1111+alderman+drive+alpharetta+ga/@34.0956988,-84.2451897,3a,75y,71.99h,90t/data=!3m7!1e1!3m4!1sbs06o0IhMfK-DFkFE9HloA!2e0!7i13312!8i6656!4b1!4m2!3m1!1s0x0:0xa7a2923026b2a590!6m1!1e1
Paying $2400 a month lease contract for 2yrs for TITLE KING, INc.
Seems very REAL and not a PO BOX or a scam.
NO CHARTS.COM
[-chart]stockcharts.com/c-sc/sc?s=NECA&p=w&b=5&g=1&id=p49531522170[/chart]
yes NECA looking very moveable with zero toxic, forget those .0035 plays we will pass them .0006/7 HNSS. LOL
Announcement: The Ghost Board of Moderators nominates New America Energy Corp. (NECA) to the nomination list of companies not having toxic debt.
MMMW having only 67 million authorized shares could bring an interesting supply and demand issue in addition to other good MMMW features. Somebody was placing a bid for just under 5% of the outstanding shares today. Good but strange.
NECA .0005s test slap, zero dilutition, doesnt take much to move her
$PMCB Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
Source: Marketwired
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
BONITA, CA-(Marketwired - October 09, 2015) - The combination of PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has already won the FDA's "Orphan Drug" status here in the U.S., and now it seems the company will also be awarded the “Orphan Designation” with the European Medicines Agency (EMA), which would guarantee 10 years of competition-free marketing when the pancreatic cancer treatment is approved.
In the world of biopharma, it doesn't take long for a company to copy or mimic a popular, successful drug. In fact, for some less-common diseases, the industry realizes that merely sharing the revenue generated by a small niche may not even be worth the effort, meaning those rare or difficult-to-treat diseases often go completely unaddressed. If all goes as planned for PharmaCyte and its novel pancreatic cancer treatment, not only does it stand to introduce a game-changing therapy to the market, it could be rewarded for its efforts with years of exclusive marketing rights in for its patented treatment.
In the U.S., the FDA has given PharmaCyte the Orphan Designation, which will give the company 7 years of marketing exclusivity when the company’s pancreatic cancer treatment is approved. Now, the company has hinted that it is close to securing the Orphan Designation with the EMA in Europe, which will offer PharmaCyte 10 years of marketing exclusivity when its treatment is approved.
PharmaCyte Biotech is the developer of a live-cell encapsulation platform biotechnology known as Cell-in-a-Box®. In simplest terms, Cell-in-a-Box is a means of encapsulating and implanting living cells into a patient's body where they can drive a specific therapeutic effect. In the case of PharmaCyte's pancreatic cancer therapy, these encapsulations (about the size of the head of a pin) contain cells that produce an enzyme, which activates a cancer-killing drug called ifosfamide.
The advantage of this method of drug-activation is pinpoint placement within the body.
Ifosfamide is usually converted to its cancer-killing form in the liver. It works, but the bulk of the drug gets "lost" before reaching the pancreatic tumor given the pancreas is the last organ on the circulatory system. By moving the “activation site” from the liver to the site of the tumor - by implanting about 300 of these pinhead-sized encapsulations at the site of the tumor - ifosfamide isn't converted into its useful form until the last possible moment, insuring maximum impact of the drug at a minimal dosage.
And, the company has already seen compelling results with this approach through the first part of its phase 1/2 trials.
In a test comparing the benefit of the Cell-in-a-Box delivery of ifosfamide versus historical results for the drug gemcitabine alone, the PharmaCyte approach improved the median survival time from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors of the study's patients increased from 18% to 36%.
That was enough to get the FDA's attention, which has since granted the combination of Cell-in-a-Box and ifosfamide an "Orphan Drug" designation. Better yet, per Wednesday's news release, the company is in the process of securing the same Orphan Designation with the European Medicines Agency according to PharmaCyte CEO Kenneth L. Waggoner.
The FDA and other sovereign agencies created the Orphan Drug Designation as a means to encourage the development of treatments for rare diseases that may not otherwise be addressed by the industry. One of the more advantageous benefits of the Orphan Drug status is generous tax breaks, though the biggest upside may be multi-year marketing exclusivity. The FDA's marketing-exclusivity rights for its designated Orphan Drugs extend for 7 years after the drug is approved. The EMA's orphan drug program is similar, though it guarantees marketing exclusivity for a period of 10 years.
That's practically an eternity for a drug, during which time - if ifosfamide and Cell-in-a-Box are approved - PharmaCyte Biotech would continue to develop its biotechnology as a means of treating diabetes, and even brain cancer.
At stake is a piece of an underserved $2 billion pancreatic cancer market, a market that could prove very lucrative with the therapy's exclusive marketing rights being in place for several years after any approval.
The next step is the upcoming phase 2b clinical trial using Cell-in-a-Box® with low doses of the drug ifosfamide in hopes of providing patients with a treatment that meets a current unmet medical need in the treatment of advanced pancreatic cancer.
Read more articles and our research report on PharmaCyte Biotech atwww.smallcapnetwork.com.
About SmallCap Network
The SmallCap Network is an electronic publication committed to providing our readers with useful information on publicly traded companies. SmallCap Network sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinion about the company and the trading market for their securities. Principals of the SmallCap Network may also purchase or sell securities of the companies in the open market from time to time. The positions that the SmallCap Network or its principals maintain in securities of the companies are disclosed here and should be considered in making an investment decision regarding companies mentioned on the SmallCap Network site. The SmallCap Network may be deemed to have a conflict of interest between its open market activity and positions in these securities and the timing of and opinions expressed in its publications concerning these companies. SmallCap Network has been compensated $10,000 and has been pledged a fee of $4,000 per month by a third party for market awareness and other advertising services on PMCB.
All statements and opinions expressed herein are those of the editors and staff of SmallCap Network and are subject to change without notice. The SmallCap Network maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell any of the securities mentioned. SmallCap Network, its principals or employees are not registered investment advisors or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.
Furthermore, SmallCap Network has not independently verified such information provided within our publication. Readers are encouraged to do their own due diligence before investing in any securities mentioned in this article. Investing in securities is speculative and carries a high degree of risk. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found athttp://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. The information found in this Newsletter is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the expressed, written consent of The SmallCap Network.
CONTACT INFORMATION
Contact:
SmallCap Network
customerservice@smallcapnetwork.com
add all littles adds one big lot.
Been busy with many little things lately.
$PMCB PharmaCyte Biotech Designs Clinical Trial to Meet Critical Unmet Medical Need
Source: GlobeNewswire Inc.
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its upcoming clinical trial will determine whether its pancreatic cancer treatment (Cell-in-a-Box® capsules + low-doses of ifosfamide) can satisfy a critical unmet medical need for patients with pancreatic cancer when the “gold standard” treatment is no longer effective at treating the disease. Currently there is no adequate alternative treatment available.
Translational Drug Development (TD2), along with Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, and the Chairman of PharmaCyte Biotech’s Scientific Advisory Board, and Dr. Manuel Hidalgo, the Director of Clinical Research at the Spanish National Cancer Research Center and a member of PharmaCyte’s Scientific Advisory Board, provided invaluable information and guidance to PharmaCyte in the design of its clinical trial in advanced pancreatic cancer. The trial is designed to provide an effective treatment for the large percentage of patients who no longer respond to the “gold standard” for the treatment of advanced pancreatic cancer. There are few options for further treatment available to them, and these are only marginally effective. PharmaCyte’s team believes that it is here that PharmaCyte’s pancreatic cancer treatment could play an important role in what has been termed a “consolidation therapy” in the further treatment of these patients.
As previously explained by Dr. Löhr in his recent article on the unmet medical need being targeted by PharmaCyte, chemotherapy may be able to prevent relapse in patients whose pancreatic cancer tumors have been removed surgically, but this situation occurs in only 20% of all patients at best. The large remaining group of patients whose tumors are inoperable normally receive treatment designed to prolong survival. Recent progress in the chemotherapy of pancreatic cancer has resulted in survival rates of between 10 and 11 months through the use of either the combination of gemcitabine and nab-paclitaxel (Abraxane®), the “gold standard” for the treatment of pancreatic cancer, or a harsh combination of conventional cancer chemotherapy drugs known as FOLFIRINOX that not all patients can tolerate.
However, for patients whose tumors neither progress nor show signs of tumor reduction, there is no effective treatment alternative. PharmaCyte’s treatment of pancreatic cancer may fill this critical unmet medical need for these patients. This need and opportunity caused PharmaCyte to completely redesign its clinical trial.
In addition to examining the antitumor effectiveness of PharmaCyte’s pancreatic cancer treatment, the effect of the treatment on the development and progression of the pain associated with pancreatic cancer will also be measured in the clinical trial. Because this “pain” aspect will be studied, it will no longer be necessary to conduct a separate “pain” clinical trial as originally planned. The pain associated with pancreatic cancer is both unbearable and untreatable in about 25% of patients with the disease.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are extremely grateful to TD2, Dr. Löhr and Dr. Hidalgo for their insight and guidance in designing our clinical trial. We believe that their identification of the opportunity for our pancreatic cancer treatment to satisfy a critical unmet medical need will give our pancreatic cancer treatment the greatest opportunity for success. The inclusion of the previously planned separate pain trial in the upcoming trial will also eliminate the need for a costly and time-consuming separate trial to study this aspect of our pancreatic cancer treatment. Over the next week or so, we will be laying out our new trial design and the other changes related to the upcoming clinical trial.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte Biotech’s treatment for cancer involves encapsulating genetically modified live cells capable of converting an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
Primary Logo
good evening, what ya been doing ?????
re;
MMMW moving without news. A little news on revenue or its new solar tracker could create fireworks. No toxic debt with $500,000 market cap.
MMMW moving without news. A little news on revenue or its new solar tracker could create fireworks. No toxic debt with $500,000 market cap.
At less than $500,000 market cap and no toxic debt, $MMMW could easily go up much further with any news including some revenue update with its new solar tracker.
$MMMW nice closed and up 48.1% today
Go $MMMW
Alert $MMMW and watch $PMCB ( Both great for the long term too).
$PMCB Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
Source: Marketwired
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
BONITA, CA-(Marketwired - October 09, 2015) - The combination of PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has already won the FDA's "Orphan Drug" status here in the U.S., and now it seems the company will also be awarded the “Orphan Designation” with the European Medicines Agency (EMA), which would guarantee 10 years of competition-free marketing when the pancreatic cancer treatment is approved.
In the world of biopharma, it doesn't take long for a company to copy or mimic a popular, successful drug. In fact, for some less-common diseases, the industry realizes that merely sharing the revenue generated by a small niche may not even be worth the effort, meaning those rare or difficult-to-treat diseases often go completely unaddressed. If all goes as planned for PharmaCyte and its novel pancreatic cancer treatment, not only does it stand to introduce a game-changing therapy to the market, it could be rewarded for its efforts with years of exclusive marketing rights in for its patented treatment.
In the U.S., the FDA has given PharmaCyte the Orphan Designation, which will give the company 7 years of marketing exclusivity when the company’s pancreatic cancer treatment is approved. Now, the company has hinted that it is close to securing the Orphan Designation with the EMA in Europe, which will offer PharmaCyte 10 years of marketing exclusivity when its treatment is approved.
PharmaCyte Biotech is the developer of a live-cell encapsulation platform biotechnology known as Cell-in-a-Box®. In simplest terms, Cell-in-a-Box is a means of encapsulating and implanting living cells into a patient's body where they can drive a specific therapeutic effect. In the case of PharmaCyte's pancreatic cancer therapy, these encapsulations (about the size of the head of a pin) contain cells that produce an enzyme, which activates a cancer-killing drug called ifosfamide.
The advantage of this method of drug-activation is pinpoint placement within the body.
Ifosfamide is usually converted to its cancer-killing form in the liver. It works, but the bulk of the drug gets "lost" before reaching the pancreatic tumor given the pancreas is the last organ on the circulatory system. By moving the “activation site” from the liver to the site of the tumor - by implanting about 300 of these pinhead-sized encapsulations at the site of the tumor - ifosfamide isn't converted into its useful form until the last possible moment, insuring maximum impact of the drug at a minimal dosage.
And, the company has already seen compelling results with this approach through the first part of its phase 1/2 trials.
In a test comparing the benefit of the Cell-in-a-Box delivery of ifosfamide versus historical results for the drug gemcitabine alone, the PharmaCyte approach improved the median survival time from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors of the study's patients increased from 18% to 36%.
That was enough to get the FDA's attention, which has since granted the combination of Cell-in-a-Box and ifosfamide an "Orphan Drug" designation. Better yet, per Wednesday's news release, the company is in the process of securing the same Orphan Designation with the European Medicines Agency according to PharmaCyte CEO Kenneth L. Waggoner.
The FDA and other sovereign agencies created the Orphan Drug Designation as a means to encourage the development of treatments for rare diseases that may not otherwise be addressed by the industry. One of the more advantageous benefits of the Orphan Drug status is generous tax breaks, though the biggest upside may be multi-year marketing exclusivity. The FDA's marketing-exclusivity rights for its designated Orphan Drugs extend for 7 years after the drug is approved. The EMA's orphan drug program is similar, though it guarantees marketing exclusivity for a period of 10 years.
That's practically an eternity for a drug, during which time - if ifosfamide and Cell-in-a-Box are approved - PharmaCyte Biotech would continue to develop its biotechnology as a means of treating diabetes, and even brain cancer.
At stake is a piece of an underserved $2 billion pancreatic cancer market, a market that could prove very lucrative with the therapy's exclusive marketing rights being in place for several years after any approval.
The next step is the upcoming phase 2b clinical trial using Cell-in-a-Box® with low doses of the drug ifosfamide in hopes of providing patients with a treatment that meets a current unmet medical need in the treatment of advanced pancreatic cancer.
Read more articles and our research report on PharmaCyte Biotech atwww.smallcapnetwork.com.
About SmallCap Network
The SmallCap Network is an electronic publication committed to providing our readers with useful information on publicly traded companies. SmallCap Network sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinion about the company and the trading market for their securities. Principals of the SmallCap Network may also purchase or sell securities of the companies in the open market from time to time. The positions that the SmallCap Network or its principals maintain in securities of the companies are disclosed here and should be considered in making an investment decision regarding companies mentioned on the SmallCap Network site. The SmallCap Network may be deemed to have a conflict of interest between its open market activity and positions in these securities and the timing of and opinions expressed in its publications concerning these companies. SmallCap Network has been compensated $10,000 and has been pledged a fee of $4,000 per month by a third party for market awareness and other advertising services on PMCB.
All statements and opinions expressed herein are those of the editors and staff of SmallCap Network and are subject to change without notice. The SmallCap Network maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell any of the securities mentioned. SmallCap Network, its principals or employees are not registered investment advisors or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.
Furthermore, SmallCap Network has not independently verified such information provided within our publication. Readers are encouraged to do their own due diligence before investing in any securities mentioned in this article. Investing in securities is speculative and carries a high degree of risk. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found athttp://www.sec.gov/consumer/cyberfr.htm.
Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. The information found in this Newsletter is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the expressed, written consent of The SmallCap Network.
CONTACT INFORMATION
Contact:
SmallCap Network
customerservice@smallcapnetwork.com
when does the stop sign come off ? a/s has not been changed from sos and otc markets correlate
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=%252fo7mAS1btY7pjHSZn0vTUg%253d%253d&nt7=0
I will do some DD today ~ thanks
Thanks for the great words, WarChest.
EEGI HEATING UP BUDDY!!!
THEY JUST PICKED UP CEO FROM ANAS (5 HOUR HIGH)
EXPECTING AN MJ PLAY FOR EEGI GOING FORWARD
Mass Megawatts $MMMW has less than $300,000 market cap while no revenue solar companies have market caps of several times higher with some no revenue solar companies having market caps of greater than $10 million. The patent pending, Mass Megawatts $MMMW 'Solar Tracking System' (STS) is a complete solar power system that’s designed to continually adjust the position of solar panels to receive the optimal level of direct sunlight throughout the day. Unlike other solar tracking technologies, the Mass Megawatts STS utilizes a low-cost structure that adds stability to the overall solar-power system while improving energy production levels for the customer.
There are many advantages to owning a Solar Tracking System (STS) …
• Increases solar energy production by 30+% over traditional solar power systems
• Provides an affordable, solar-power solution for home and business use
• Reduces (or eliminates) the need to purchase high-priced electricity from the local utility
• Significantly lowers your monthly electric bill with Net Metering.
• Provides an impressive ROI of 20 to 40% with payback occurring within a few years
• Available federal, state, and local incentives can reduce your costs dramatically…
o 30% Federal Tax Credit on full purchase price of STS (no limit)
o State rebates, such as the Commonwealth rebate (up to $4,250)
o State Tax credit, such as MA credit of $1,000
o Sale of generated SRECs, which can add thousands in yearly revenue
• Flexible purchase plans offered by Mass Megawatts can limit out-of-pocket costs.
• Mass Megawatts handles everything, including installation and servicing, etc.
• STS is designed to withstand extreme weather and high winds
• Comes with a full performance guarantee from Mass Megawatts
• Helps our environment by reducing the demand for fossil-fuel energy sources that generate harmful CO2 emissions
Some factors that contribute to a favorable return with a Solar Tracking System from Mass Megawatts.
• Patented, low-cost, solar-power generation technology with guaranteed performance.
Mass Megawatts has developed proprietary, solar-power generation technology that utilizes an innovative structural design that combines a simple, yet robust, A-frame design with a low-cost, protective outer-wall. Using a non-electrical, and passive, tracking technology, the solar panels are automatically repositioned throughout the day as the sun's position travels from east to west. With ground fittings secured at multiple points, the system is designed to handle extreme weather and winds up to 120 mph.
The proven tracking technology allows the panels to receive more direct sunlight and to generate more solar power for the customer. With this system, solar energy production is increased by up to 30% compared to traditional, stationary configurations. Future versions of the STS will also offer a dual-tracking capability, which can improve solar power generation levels by an additional 10%.
The STS utilizes proven, solar components and technologies including high-quality solar panels, inverters, and tracking system technologies. This delivers a reliable, and predictive, energy generation result. The added stability of the STS improves MTBF, which leads to a reduction in down-time and improved performance for the customer. This is achieved with the patented, low-cost framework and protective outer wall, developed by Mass Megawatts.
In addition, “Technology risk” with a Mass Megawatts STS is effectively eliminated with a full, 10 year, operational and performance guarantee. Simply stated, if the wind system doesn’t produce the level of energy that’s expected, you will receive a credit for the difference in lost revenues.
• Reducing and eliminating financial risk with guaranteed, government incentives.
Federal, state, and local incentives offer a number of benefits for individuals and businesses that invest in solar power.
• Substantially reduces the total cost of a solar power system.
• Improves the return on investment and shortens the payback-period.
• Aids in securing third party financing for a solar power system.
With favorable rebates and tax incentives, a large percentage of capital costs can be recouped in the first year of service, while providing for substantial, ongoing revenues. This greatly reduces financial risk by allowing customers to more quickly reduce outstanding debt, shorten the investment payback period, and to increase ROR
on nwav ?????
New Wave Holdings, Inc. (NWAV)
if same mgmt.
history of reverse splits.
New Wave Holdings Inc. (NWAV
http://investorshub.advfn.com/New-Wave-Holdings-Inc-NWAV-4614/?NextStart=61398
Your welcome.
A leading killer of OTC stock prices is "floorless convertible debt", also known as "Death Spiral Financing"
This Board is now accepting nominations of OTC public companies to be verified of having no floorless convertible debt. Please send your request for nominations as a message post. As of August 8,2016 thirty eight requests for nominations for verification as the first step in the process have been approved. More nomination are expected shortly.
Congratulations to the following companies
nominated for verification review of having no floorless toxic convertibles are;
Mass Megawatts Wind Power, Inc (MMMW)
Iteknik Holding Corporation (ITKH)
United American Petroleum (UAPC)
Valmie Resources, Inc. (VMRI)
Cardica, Inc. (CRDC)
Sunset Capital Assets, Inc. (SNST)
Players Network (the)(PNTV)
Boreal Water Collection, Inc. (BRWC)
Gazprom Oao (OGZPY)
Kiwa-Bio-Tech Products Group (KWBT)
Pharmacyte Biotech, Inc. (PMCB)
Jns Holdings Corporation (JNSH)
Mmrglobal,Inc. (MMRF)
Fitbit, Inc. (FIT)
One World Holdings,Inc. (OWOO)
International Spirit and Beverage Group, Inc.(ISBG)
Stratasys, LTD (SSYS)
CMG Holdings Group, Inc. (CMGO)
Royale Energy,Inc. (ROYL)
On4 Communications, Inc. (ONCI)
Polaris International Holdings, Inc. (PIHN)
Discovery Minerals, LTD (DSCR)
Well Power,Inc. (WPWR)
Tungsten Corp. (TUNG)
Zalemark Holdings Co., Inc. (ZMRK)
Daniels Corporate Advisory Co, Inc. (DCAC)
Idglobal Corp. (IDGC)
National Energy Services, Inc. (NESV)
Ism International, Inc. (ISML)
Praxsyn Corporation (PXYN)
Cannabis Science. Inc. (CBIS)
India Ecommerce Corp. (IEEC)
Q Lotus Holdings Inc. (QLTS)
New Wave Holdings, Inc. (NWAV)
Global Equity International (GEQU)
New America Energy Corp. (NECA)
Medical Marijuana, Inc. (MJNA)
Mike the Pike Productions, Inc. (MIKP)
The following information is from the United States Securities and Exchange Commission website articulating the risk related to Convertible Debt
A "convertible security" is a security—usually a bond or a preferred stock—that can be converted into a different security—typically shares of the company's common stock. In most cases, the holder of the convertible determines whether and when to convert. In other cases, the company has the right to determine when the conversion occurs.
Companies generally issue convertible securities to raise money. Companies that have access to conventional means of raising capital (such as public offerings and bank financings) might offer convertible securities for particular business reasons. Companies that may be unable to tap conventional sources of funding sometimes offer convertible securities as a way to raise money more quickly. In a conventional convertible security financing, the conversion formula is generally fixed - meaning that the convertible security converts into common stock based on a fixed price. The convertible security financing arrangements might also include caps or other provisions to limit dilution (the reduction in earnings per share and proportional ownership that occurs when, for example, holders of convertible securities convert those securities into common stock).
By contrast, in less conventional convertible security financings, the conversion ratio may be based on fluctuating market prices to determine the number of shares of common stock to be issued on conversion. A market price based conversion formula protects the holders of the convertibles against price declines, while subjecting both the company and the holders of its common stock to certain risks. Because a market price based conversion formula can lead to dramatic stock price reductions and corresponding negative effects on both the company and its shareholders, convertible security financings with market price based conversion ratios have colloquially been called "floorless", "toxic," "death spiral," and "ratchet" convertibles.
Both investors and companies should understand that market price based convertible security deals can affect the company and possibly lower the value of its securities. Here's how these deals tend to work and the risks they pose:
The company issues convertible securities that allow the holders to convert their securities to common stock at a discount to the market price at the time of conversion. That means that the lower the stock price, the more shares the company must issue on conversion. | |
The more shares the company issues on conversion, the greater the dilution to the company's shareholders will be. The company will have more shares outstanding after the conversion, revenues per share will be lower, and individual investors will own proportionally less of the company. While dilution can occur with either fixed or market price based conversion formulas, the risk of potential adverse effects increases with a market price based conversion formula. | |
The greater the dilution, the greater the potential that the stock price per share will fall. The more the stock price falls, the greater the number of shares the company may have to issue in future conversions and the harder it might be for the company to obtain other financing. |
Before you decide to invest in a company, you should find out what types of financings the company has engaged in - including convertible security deals - and make sure that you understand the effects those financings might have on the company and the value of its securities. You can do this by researching the company in the SEC's EDGAR database and looking at the company's registration statements and other filings. Even if the company sells convertible securities in a private, unregistered transaction (or "private placement"), the company and the purchaser normally agree that the company will register the underlying common stock for the purchaser's resale prior to conversion. You'll also find disclosures about these and other financings in the company's annual and quarterly reports on Forms 10-K and 10-Q, respectively, and in any interim reports on Form 8-K that announce the financing transaction.
If the company has engaged in convertible security financings, be sure to ascertain the nature of the convertible financing arrangement - fixed versus market price based conversion ratios. Be sure you fully understand the terms of the convertible security financing arrangement, including the circumstances of its issuance and how the conversion formula works. You should also understand the risks and the possible effects on the company and its outstanding securities arising from the below market price conversions and potentially significant additional share issuances and sales, including dilution to shareholders. You should be aware of the risks arising from the effects of the purchasers and other parties trading strategies, such as short selling activities, on the market price for the company's securities, which may affect the amount of shares issued on future conversions.
Companies should also understand the terms and risks of convertible security arrangements so that they can appropriately evaluate the issues that arise. Companies entering into these types of convertible securities transactions should understand fully the effects that the market price based conversion ratio may have on the company and the market for its securities. Companies should also consider the effect that significant share issuances and below market conversions have on a company's ability to obtain other financing.
Companies or investors seeking to learn more about the SEC's registration requirements for common stock issuable upon conversion of unregistered convertible securities, including the timing of the filing of the resale registration statement and the appropriate form that the company may use to register the resale, should consult the Division of Corporation Finance's Compliance and Disclosure Interpretations.
Bloomberg follow up on DEATH SPIRAL FINANCING- incredible article.
Remember, Bloomberg did a first article about "Magna" and Josh Sason who runs it- how they provide financing to cash desperate penny stocks (such as Bioheart, BHRT which has a forum here on I-HUB and did qty-2 Magna financing deals end of 2014).
This was Bloombergs first excellent piece of financial journalism- where a highly reputable main stream financial news and investigative journalism group looked into the sorted world of what's known as "death spiral" or "floorless convertible debt" as is discussed here.
Here's that first article:
http://www.bloomberg.com/news/articles/2015-03-12/josh-sason-made-millions-from-penny-stock-financing
Here is the latest article- written by a Bloomberg writer (and this guy is no duffer, look at his resume on the upper right-hand column: Investment banker, mergers and acquisitions lawyer among other attributes on a very flush, "expert" quality resume)
Here's his follow up on the first Bloomberg piece- it's an incredible glimpse, with explanations, into the sorted world of penny stock "death spiral" financing and how it all works. A stunning read IMO. Amazing stuff that some news source as credible as Bloomberg is finally peeling back the layers and revealing this sorted, dark world of penny stock financing IMO- real amazing read:
http://www.bloombergview.com/articles/2015-03-12/death-spiral-convertible-financier-has-a-lot-of-fun
An amazing read IMO- another "best of" in explaining some of the inner workings of the "convertible debt" dark recesses of the penny stock finance world.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |